≥76 years

\<12 years.

Participation in another clinical study in the past 30 days or planned during study conduct.

Severe COVID19

Intake of antimicrobial, antiviral, immune suppressive substances.

Surgical intervention in the 3 months prior enrolment

Known diabetes mellitus.

Known and medicated atopy or asthma.

Cystic Fibrosis, bronchopulmonary dysfunction, COPD.

Known immune system disorders and degenerative disorders (autoimmune disorders, AIDS, leukemia, lymphoma, myeloma).

Known metabolic or resorption disorders.

Known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidney insufficiency).

Serious health conditions (limited general condition, auto-immune diseases, tumorous diseases, neurological disorders or serious Covid-19)

Known allergies to plants of the compositae family (e.g. chamomile or dandelion) or to one of the compounds in the investigational product

Known pregnancy.

Echinaforce COVID-19 Shedding Study